Drug intelligence / Profile preview

414-1

Development stage: Preclinical
Lead developer: Active Motif
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intranasal

Overview

414-1 is a human IgG monoclonal antibody isolated by Active Motif from recovered COVID-19 patients. Diomics licensed this antibody to develop Dioguard, a prophylactic nasal spray intended to neutralize the SARS-CoV-2 virus. The nasal spray utilizes Diomics' proprietary Diomat nanobead technology for delivery, aiming to extend the antibody's residency in the nasal mucosa. This approach is designed to provide a non-invasive preventative measure against COVID-19, reduce asymptomatic spread, and offer protection.

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on 414-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 414-1.

Explore the full profile